香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年12月1日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫雲霞女士、羅樨女士及顧靜良先生，及獨立非執行董事張帆先生、楊福全 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2025-049 北京昭衍新药研究中心股份有限公司 董事、监事及高管减持 A 股股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董监高持股的基本情况 2025 年 9 月 9 日披露减持计划公告前，北京昭衍新药研究中心股份有限公 司（以下简称"公司"）董事、副总经理孙云霞持有公司股票 2,698,907 股，占公 司总股本 0.3601%；董事、总经理、董事会秘书高大鹏持有公司股票 288,746 股， 占公司总股本 0.0385%；董事、副总经理顾静良持有公司股票 269,801 股，占公 司总股本 0.0360%；监事李叶持有公司股票 102,481 股，占公司总股本 0.0137%； 财务总监于爱水持有公司股票 34,104 股，占公司总股本 0.0046%。上述股份来源 于首发前限售股份、股权激励股份及公司资本公积金转增股份等。 孙云霞、高大鹏、顾静良、李叶、于爱水于 2025 年 9 月 9 日披露了减持计 划，自减持计划公 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 603127 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 630,482,128 | RMB | | 1 RMB | | 630,482,128 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 630,482,128 | RMB | | 1 RMB | | 630,482,128 | 本月底法定/註冊股本總額： RMB 749,477,334 備註： 第 1 頁 共 11 頁 v 1.1.1 公司名稱: 北京昭衍新藥研究中心股份有限公司 ...

Core Viewpoint - The stock of Zhaoyan New Drug has shown significant volatility, with a year-to-date increase of 70.06%, but recent declines in the short term raise concerns about its performance [1][2]. Group 1: Stock Performance - As of November 25, Zhaoyan New Drug's stock price increased by 2.02% to 28.23 CNY per share, with a trading volume of 162 million CNY and a turnover rate of 0.92%, resulting in a total market capitalization of 21.158 billion CNY [1]. - The stock has experienced a decline of 9.89% over the last five trading days, 15.48% over the last 20 days, and 14.14% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on September 15 [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million CNY, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.706 million CNY [2]. - The company has distributed a total of 703 million CNY in dividends since its A-share listing, with 356 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug reached 96,500, an increase of 57.61% compared to the previous period [2]. - The top ten circulating shareholders include notable funds, with Huabao Zhongzheng Medical ETF holding 12.484 million shares, a decrease of 2.1693 million shares from the previous period, while new shareholders include Guangfa Small Cap Growth Mixed Fund [3].

智通财经APP获悉，根据2025年11月21日披露数据，长飞光纤光缆（06869）、国富氢能（02582）、龙 蟠科技（02465）港股通持股占比增加值最大，分别增加1.36%、1.28%、0.99%；恆生中国企业 （02828）、盈富基金（02800）、昭衍新药（06127）港股通持股占比减少值最大，分别减 少-1.80%、-1.02%、-0.83%。 在最近有统计数据的5个交易日内，国富氢能（02582）、巨星传奇（06683）、亿华通（02402）港股通 持股占比增加值最大，分别增加8.87%、4.38%、3.39%；恆生中国企业（02828）、盈富基金 （02800）、丘鈦科技（01478）港股通持股占比减少值最大，分别减少-6.67%、-2.66%、-1.73%。 具体数据如下（交易所数据根据T+2日结算）： 1、港股通最新日占比增持榜（前20名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 长飞光纤光缆(06869) | +1.36% | 59.08% | | 国富氢能(02582) | +1.28% | 16.43% | | 龙蟠科技(0246 ...

Core Viewpoint - The CXO sector in the A-share market is experiencing significant growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters, driven by internationalization and policy support for innovative drug companies [1][2]. Group 1: Industry Trends - Three major trends are emerging in the innovative drug sector: 1. Deepening internationalization 2.0, with an expected 103 license-out transactions and a record upfront payment of $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2]. 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a commercial insurance directory for innovative drugs [2]. 3. Continuous technological breakthroughs, with advancements in ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2]. Group 2: Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing, particularly for CDMO companies with strong international capabilities and leading clinical CROs [2]. - The recovery of the upstream industry chain is significant, with ample room for increasing domestic production rates, driven by smart and digital production alongside international expansion [2]. - The capital market's recovery in financing activities and the expansion of innovative drug transactions abroad, combined with a potential recovery in domestic innovative drug R&D demand, are expected to boost CXO companies' performance in the second half of the year [1]. Group 3: Key Companies - Leading companies in the CXO sector include: - Kelaiying (06821) - Kanglong Chemical (03759) - Zhaoyan New Drug (06127) - WuXi Biologics (02269) - WuXi AppTec (02359) [3].

Group 1 - The core viewpoint of the news is that Zhaoyan New Drug's stock has experienced a decline recently despite a significant increase in its price year-to-date, indicating potential volatility in the market [1][2]. - As of November 20, Zhaoyan New Drug's stock price was 29.14 yuan per share, with a market capitalization of 21.84 billion yuan and a trading volume of 1.24 billion yuan [1]. - The company has seen a year-to-date stock price increase of 75.54%, but it has declined by 13.12% in the last five trading days [1]. Group 2 - Zhaoyan New Drug operates primarily in the pharmaceutical industry, focusing on non-clinical safety evaluation services and preclinical research services, with 95.59% of its revenue coming from non-clinical research services [1][2]. - For the period from January to September 2025, Zhaoyan New Drug reported a revenue of 985 million yuan, a year-on-year decrease of 26.23%, while its net profit attributable to shareholders increased by 214.79% to 80.71 million yuan [2]. - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed in the last three years [3]. Group 3 - As of September 30, 2025, the number of shareholders for Zhaoyan New Drug increased by 57.61% to 96,500, indicating growing interest in the stock [2]. - The top ten circulating shareholders include notable funds, with Hua Bao Zhong Zheng Medical ETF holding 12.48 million shares, a decrease of 2.17 million shares from the previous period [3]. - New shareholders include Guangfa Small Cap Growth Mixed Fund, which holds 10.28 million shares, and Guangfa Innovation Upgrade Mixed Fund, holding 9.21 million shares [3].

Core Points - The announcement details the release of part of the pledged shares by shareholder Gu Meifang, who currently holds 10,322,035 shares, representing 1.38% of the total share capital of the company [1] - After the release of the pledge, Gu Meifang has a total of 5,000,000 pledged shares, which accounts for 48.44% of her holdings [1] - The company previously announced a cash dividend of 0.40 yuan per share (before tax) and a capital reserve increase of 0.4 shares per share on July 19, 2023 [1] Summary of Key Information - As of the announcement date, Gu Meifang's pledged shares increased from 1,000,000 to 1,400,000 shares following the capital increase [1] - The notice of the release of pledged shares was received on November 17, 2025, and the company is providing specific details in this announcement [1]

Core Viewpoint - The company announced that shareholder Gu Meifang has released the pledge on 1.4 million shares, reducing the total pledged shares to 5 million, which is 48.44% of her holdings [1] Summary by Relevant Sections - **Shareholder Actions** - Gu Meifang has released the pledge on 1.4 million shares as of November 17, 2025 [1] - After the release, Gu Meifang holds a total of 10.322 million shares, representing 1.38% of the company's total share capital [1] - **Pledged Shares** - Following the release of the pledge, the total number of pledged shares held by Gu Meifang is now 5 million [1] - This represents 48.44% of her total shareholding [1]

Group 1 - The core point of the article is that Zhaoyan New Drug (SH 603127) announced the release of share pledges by Gu Meifang, who holds approximately 10.32 million shares, accounting for 1.38% of the company's total share capital [1] - After the release of the pledge, Gu Meifang has a total of 5 million shares pledged, which represents 48.44% of her holdings [1] - For the year 2024, Zhaoyan New Drug's revenue composition is projected to be 95.0% from preclinical research services, 4.95% from clinical services, and 0.04% from sales of laboratory animals and related products [1] Group 2 - As of the announcement, Zhaoyan New Drug has a market capitalization of 23.8 billion yuan [1]